Compare NATL & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NATL | VCYT |
|---|---|---|
| Founded | 2023 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.1B |
| IPO Year | 2023 | 2013 |
| Metric | NATL | VCYT |
|---|---|---|
| Price | $44.17 | $49.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $45.60 | $44.00 |
| AVG Volume (30 Days) | 523.9K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 73.98 | ★ 164.52 |
| EPS | 0.29 | ★ 0.35 |
| Revenue | ★ $4,354,000,000.00 | N/A |
| Revenue This Year | $6.13 | $13.76 |
| Revenue Next Year | $4.24 | $12.35 |
| P/E Ratio | $152.66 | ★ $135.23 |
| Revenue Growth | ★ 0.86 | N/A |
| 52 Week Low | $23.56 | $22.61 |
| 52 Week High | $48.50 | $50.71 |
| Indicator | NATL | VCYT |
|---|---|---|
| Relative Strength Index (RSI) | 47.17 | 65.07 |
| Support Level | $43.62 | $40.27 |
| Resistance Level | $46.20 | $50.63 |
| Average True Range (ATR) | 0.49 | 2.42 |
| MACD | -0.05 | -0.28 |
| Stochastic Oscillator | 25.30 | 85.45 |
NCR Atleos Corp is a financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers, and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels, all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware, and its proprietary Allpoint network. Atleos manages its operations in the following segments: Self-Service Banking, which generates maximum revenue, Network, and Telecommunications and Technology. Geographically, it derives maximum revenue from the U.S.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).